Sleep-disordered breathing in patients with newly diagnosed lung cancer

Abstract

Background and objective: There are currently no data on the prevalence of sleep-disordered breathing (SDB) in patients with newly-diagnosed lung cancer. This might be of interest given that SDB is associated with increased cancer incidence and mortality. Furthermore, intermittent hypoxia has been linked with tumor growth and progression. This study investigated the prevalence of SDB in patients with newly-diagnosed lung cancer. Methods: Patients with newly-diagnosed lung cancer from three centers in Germany were screened for SDB using a two-channel screening system (ApneaLink™). SDB was defined as an apnea-hypopnea index of >5/h, and was classified as moderate to severe SDB if the AHI was ≥15/h. The presence of SDB-related symptoms was assessed using the Epworth Sleepiness Scale (ESS) and the Pittsburgh Sleep Quality Index (PSQI). Results: A total of 100 patients were included. The overall prevalence of SDB was 49%; seventeen patients (17%) had moderate to severe SDB with a median AHI of 25/h (quartile [Q1 18/h, Q3 44/h]) and a median oxygen desaturation index of 21/h [10/h, 35/h]. Patients with moderate to severe SDB had mild daytime sleepiness (ESS score 8±4 vs. 6±3 in those with an AHI of Conclusions: This study showed a high prevalence of SDB in patients with newly-diagnosed lung cancer. In these patients SDB was associated with intermittent hypoxia and increased daytime sleepiness. Additional research is needed to determine whether SDB influences prognosis and morbidity in patients with lung cancer.